Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Flu Fighter Visterra Tops Up Series A Round With Cash From Gates

This article was originally published in The Pink Sheet Daily

Executive Summary

To help push an antibody flu treatment into the clinic, the biotech has added $13 million from The Gates Foundation and others to bring total Series A funding to $26 million.

You may also be interested in...

Visterra Licenses Dengue IP From MIT, Tops Off Series A To $34.2 Million

The biotech plans to file an IND for its lead antibody candidate in seasonal and pandemic flu in early 2014. It also will optimize MIT research into dengue virus to find a clinical candidate to treat dengue fever.

Genocea Gets An Injection Of Capital As Early-Stage Studies Progress

The vaccine developer tapped investors for a third round of financing as its lead programs begin clinical trials.

AAVLife: Another Gene Therapy Effort To Treat Friedreich's Ataxia

With the launch of AAVLife, Versant Ventures adds to its gene therapy portfolio, and people with Friedreich's ataxia can look to another program that takes aim at the rare inherited disease.


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts